Sanofi (SNY) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Sanofi (SNY) by buying shares or fractional shares at any major US broker, through a healthcare or large-pharma ETF that holds it, or as one holding in a thematic basket. SNY is an American Depositary Receipt (ADR): it represents shares of Sanofi S.A., a French pharmaceutical company headquartered in Paris and primarily listed on the Euronext Paris exchange, with the ADR trading in dollars on the Nasdaq. Sanofi is a large-cap, diversified drugmaker whose story centers on one blockbuster, the immunology drug Dupixent, plus a vaccines franchise and a deep late-stage pipeline. The core thesis is a defensive, dividend-paying pharma that is trying to grow through new drug launches as it prepares for Dupixent's eventual patent expiry.
SNY stock price
As of 2026-07-14, Sanofi (SNY) last closed at $43.20, down 11.0% over the past year. Over the past 52 weeks it has traded between $41.33 and $52.34.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Sanofi's investor relations page. Walnut is informational, not investment advice.
What does Sanofi (SNY) do?
Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.
Because SNY is an ADR of a euro-reporting company, its dollar results and dividend are affected by the euro-to-dollar exchange rate on top of the underlying business. In Q1 2026 Sanofi reported revenue of about 10.5 billion euros and business EPS of 1.88 euros, up roughly 14% at constant exchange rates, and reaffirmed guidance for high-single-digit sales growth in 2026 with earnings growing faster than sales. The company invested about 7.2 billion euros in R&D in 2025 (around 18% of sales) and has a pipeline of over 100 projects, including recently approved or advancing assets such as rilzabrutinib (marketed as Wayrilz) and tolebrutinib (marketed as Cenrifki in the EU). The central strategic question is whether these launches can offset Dupixent's eventual loss of exclusivity later this decade.
What's driving Sanofi (SNY)?
1. Dupixent as the growth engine
Dupixent is the largest driver of Sanofi's growth, with quarterly sales above four billion euros and 30%-plus year-over-year growth in early 2026 across its approved indications in atopic dermatitis, asthma, COPD, and more. Continued label expansions widen its addressable market. The flip side is concentration: a single product carries an outsized share of the company's growth, so any slowdown or safety issue would matter a lot.
2. Pipeline and new launches
Sanofi is trying to build the next generation of products ahead of Dupixent's eventual patent expiry. Recent milestones include rilzabrutinib (Wayrilz), a BTK inhibitor approved for immune thrombocytopenia in the US, EU, and Japan and designated a breakthrough therapy for warm autoimmune hemolytic anemia, and tolebrutinib (Cenrifki), approved in the EU for a form of secondary progressive multiple sclerosis. The company frames its R&D, aided by AI tools, as a source of first-in-class assets.
3. Vaccines franchise
Vaccines are a durable pillar, led by the RSV antibody Beyfortus (now standard of care in over 45 national immunization programs and around 1.8 billion euros in 2025 sales) plus flu vaccines and the recently acquired Heplisav-B. Vaccine revenue is seasonal and can face competition, as Beyfortus saw in the US, but the franchise diversifies the company beyond its immunology blockbuster.
4. Capital returns and focus after Opella
Having spun off consumer-health unit Opella in 2025, Sanofi is now a more focused innovative-medicines-and-vaccines company. It pays a regular dividend (a mid-single-digit percentage yield in recent quarters) and has signaled share repurchases, so total shareholder return is part of the thesis. Note that as a euro payer, the dollar dividend received by ADR holders can move with the exchange rate.
What are the risks to Sanofi (SNY)?
The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. Drug development is inherently uncertain, as the December 2025 US complete response letter for tolebrutinib in non-relapsing secondary progressive MS showed, even as the EU approved it. Because SNY is an ADR of a euro-reporting company, currency swings between the euro and dollar affect reported results and the dollar value of the dividend, adding volatility unrelated to the business. Pharma also faces pricing pressure, US drug-pricing policy, patent litigation, and competition from large rivals and biosimilars. Vaccine demand is seasonal and competitive, as Beyfortus experienced in the US market.
How is Sanofi (SNY) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sanofi's investor relations page or your broker.
- Company type: Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq)
- Market cap: ~$107 billion (approximate; among the larger global pharma names)
- Q1 2026 revenue: ~10.5 billion euros, ahead of consensus (reported figures are in euros)
- Q1 2026 business EPS: ~1.88 euros, up ~14% at constant exchange rates
- Dividend yield: Roughly a mid-single-digit percentage in recent quarters (approximate; varies with price and euro/dollar rate)
- 2026 guidance: High-single-digit sales growth at constant exchange rates, with earnings growing faster than sales
Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.
Who competes with Sanofi (SNY)?
Global large-cap pharma
Sanofi competes with diversified drug majors such as Pfizer, Novartis, AstraZeneca, Roche, Merck, and Johnson & Johnson across therapy areas and for pipeline talent and acquisitions. These names offer investors similar defensive, dividend-oriented exposure to branded medicines, and they compete directly in immunology, oncology, and specialty care.
Immunology and Dupixent-adjacent players
In immunology, the field around Dupixent includes AbbVie (with Rinvoq and Skyrizi), Amgen, and Eli Lilly, among others. Regeneron is Sanofi's development partner on Dupixent rather than a pure rival. Competition and new entrants in atopic dermatitis, asthma, and related indications are a key watch item for Sanofi's biggest growth driver.
Vaccine makers
In vaccines, Sanofi competes with GSK, Pfizer, Moderna, and others across flu, RSV, and other programs. Beyfortus, its RSV antibody, faces both maternal-immunization approaches and competing products, so vaccine market share can shift season to season based on real-world performance and pricing.
How to invest in Sanofi (SNY)
There are three common ways to get SNY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SNY sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where SNY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Sanofi (SNY)
Sanofi is a defensive, dividend-paying large-cap pharma whose growth leans heavily on Dupixent while a broad pipeline aims to fill the gap before that patent expires. It suits investors who want healthcare exposure and income, but currency and single-drug concentration are real considerations.
Build a basket around SNY with Walnut
Use Sanofi as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is SNY a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The case for it is a defensive large-cap pharma with a fast-growing blockbuster in Dupixent, a real vaccines franchise, a dividend, and a deep pipeline. The considerations against it include heavy reliance on one drug ahead of its eventual patent expiry, pipeline uncertainty, and euro-to-dollar currency swings that affect the ADR. Weigh both against your own portfolio.
What is an ADR, and what does it mean that SNY is one?
+
An American Depositary Receipt is a US-traded certificate that represents shares of a foreign company, letting Americans buy it in dollars through a normal brokerage account. SNY represents shares of Sanofi S.A., a French company primarily listed in Paris. Practically, you buy and sell SNY like any US stock, but the underlying business reports in euros, so currency moves affect your returns and dividends.
What does Sanofi actually do?
+
Sanofi is a global pharmaceutical company focused on innovative medicines and vaccines. Its biggest product is Dupixent, an immunology drug for conditions like eczema, asthma, and COPD, co-developed with Regeneron. It also runs a large vaccines business (including the RSV antibody Beyfortus) and has a broad late-stage drug pipeline. It spun off its consumer-health unit, Opella, in 2025 to focus on prescription medicines.
Why does Dupixent matter so much to Sanofi?
+
Dupixent is Sanofi's single largest and fastest-growing product, with quarterly sales above four billion euros and 30%-plus year-over-year growth in early 2026. It drives much of the company's revenue growth. That concentration is a strength today but also a risk, because the eventual loss of patent protection later this decade is the central question the rest of the pipeline must answer.
Does Sanofi pay a dividend?
+
Yes. Sanofi pays a regular dividend and has offered a mid-single-digit percentage yield in recent quarters, which is part of why some investors hold it as a defensive income name. Because the company pays in euros, the dollar amount ADR holders receive can vary with the euro-to-dollar exchange rate. Always check the latest declared dividend and yield before assuming any payout.
How does currency affect SNY?
+
Sanofi earns most of its money and reports results in euros, but SNY trades in dollars on the Nasdaq. When the euro strengthens against the dollar, reported results and the dollar value of the dividend tend to rise for US holders, and vice versa. This means SNY can move for currency reasons that have nothing to do with the underlying drug business.
What is in Sanofi's pipeline?
+
Sanofi reports a pipeline of over 100 projects and spent about 7.2 billion euros on R&D in 2025. Recent examples include rilzabrutinib (marketed as Wayrilz), a BTK inhibitor approved for immune thrombocytopenia across several regions, and tolebrutinib (Cenrifki), approved in the EU for a form of progressive multiple sclerosis. Not every candidate succeeds, as the December 2025 US complete response letter for tolebrutinib showed.
How can I get exposure to Sanofi through an ETF?
+
SNY appears in many healthcare, large-pharma, and broad international or dividend ETFs, where it sits among global drugmakers. ETF exposure spreads single-stock risk across many holdings but dilutes how much any Sanofi move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Sanofi specifically.
What are the main risks of investing in SNY?
+
The biggest risk is reliance on Dupixent ahead of its eventual patent expiry, with pipeline success uncertain, as the mixed 2025-2026 tolebrutinib decisions showed. Currency swings between the euro and dollar affect the ADR and its dividend. Pharma also faces drug-pricing pressure, US policy risk, patent litigation, biosimilar competition, and seasonal, competitive vaccine markets. These combine into a defensive but not risk-free profile.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Sanofi's investor relations page or your broker before making investment decisions.